Drug Topics
SEPTEMBER 22, 2023
Treatment with buprenorphine has more than doubled since 2009, but dosing guidelines are based on studies with people using heroin that were done before the fentanyl crisis.
Pharmacy Times
SEPTEMBER 22, 2023
Empagliflozin (Jardiance) demonstrated a 28% relative risk reduction, with an absolute risk reduction of 3.6% per patient-year at risk in the treatment of chronic kidney disease.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Drug Topics
SEPTEMBER 22, 2023
Disparities for patients with HIV who have cancer exist, and this is driven by social and structural determinants of health, as well as HIV stigma and lack of training for oncologists.
Pharmacy Times
SEPTEMBER 22, 2023
The people who come to the community pharmacy represent the surrounding population at large, making the pharmacy an ideal place to identify and recruit underrepresented patients.
Speaker: Chris Antypas and Josh Halladay
Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.
Drug Topics
SEPTEMBER 22, 2023
Limited veterinary pharmacy training is available, other than a handful of pharmacy schools that provide elective courses on the topic.
Pharmacy Times
SEPTEMBER 22, 2023
Chemotherapy, medication for attention deficit/hyperactivity disorder, glucagon-like peptide-1 agonists for weight loss and diabetes, and local anesthetics were among the drugs most affected by shortages.
Pharmacy Technician Pulse brings together the best content for pharmacy technicians from the widest variety of industry thought leaders.
Pharmacy Times
SEPTEMBER 22, 2023
Heather Moore, CPP, PharmD, highlights key contributions from pharmacists in breast cancer treatment and identifies current unmet needs in the treatment landscape.
STAT
SEPTEMBER 22, 2023
In a new test of xenotransplantation , a medical team at the University of Maryland Medical Center announced Friday that, for only the second time in history, it had transplanted a heart from a genetically engineered pig into a human. The surgeons performed the eight-hour procedure Wednesday without complications. As of Friday afternoon, the organ recipient, a 58-year-old Navy veteran and former vaccine researcher at the National Institutes of Health named Lawrence Faucette, is awake, able to si
Pharmacy Times
SEPTEMBER 22, 2023
Tune in to this episode of Pharmacy Focus to gain a deeper understanding of the AAPT Fall Seminar, the evolving landscape of pharmacy practice, and the crucial roles played by pharmacy technicians.
STAT
SEPTEMBER 22, 2023
Late last summer, Elizabeth Jacques brought her youngest daughter, Elena, for a medical checkup. At the time, Jacques and her family were experiencing housing instability after a two-year legal battle with their former landlord, who refused to clean up their unsanitary, unlivable conditions. For Jacques, it was obvious she had to leave a housing situation that was putting her family’s health at risk.
Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist
What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.
Pharmacy Times
SEPTEMBER 22, 2023
Standard amount of pre-workout should be taken at least 13.2 hours before bedtime to avoid sleep disruptions; however, there was no cut-off time for a cup of black tea.
STAT
SEPTEMBER 22, 2023
Pfizer’s new shot to protect infants against respiratory syncytial virus by vaccinating their mothers late in pregnancy won a limited recommendation Friday from an expert panel that advises the Centers for Disease Control and Prevention, clearing the way for a second product to protect babies against RSV to soon hit the market. The recommendation was accepted by CDC Director Mandy Cohen shortly after the conclusion of the panel’s meeting.
Fierce Pharma
SEPTEMBER 22, 2023
Merck and Eisai’s Keytruda-Lenvima tag team can’t seem to catch a break. | Merck and Eisai’s Keytruda-Lenvima tag team can’t seem to catch a break. Following a series of trial shortfalls this year in melanoma, colorectal cancer and head and neck squamous cell carcinoma, the duo has missed the mark in yet another set of clinical trials—this time in non-small cell lung cancer.
STAT
SEPTEMBER 22, 2023
At the height of the pandemic, when everything was shut down, a patient with whom I had a long-term relationship developed suicidal ideation. A male adolescent who lived in poverty, he was not able to call me on his smartphone because he had run out of minutes. And he was ashamed to use his parents’ telephone because of privacy issues. Fortunately, he was able to find help.
Advertisement
Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.
Fierce Healthcare
SEPTEMBER 22, 2023
Cigna is facing another lawsuit over its PxDx tool, which has garnered controversy amid concerns that the insurer is using it to reject claims en masse. | Cigna is facing another lawsuit over its PxDx tool, which has garnered controversy amid concerns that the insurer is using it to reject claims en masse.
STAT
SEPTEMBER 22, 2023
LONDON — AstraZeneca said Friday an experimental drug tamped down the progression of a certain type of breast cancer in a Phase 3 trial, a win for the company after the same drug produced underwhelming results in a lung cancer trial over the summer. The drug, called datopotamab deruxtecan or Dato-DXd for short, succeeded on one of its primary endpoints of improving progression-free survival compared to chemotherapy in certain breast cancer patients who had previously been treated with oth
Pharmacy Times
SEPTEMBER 22, 2023
The House Committee members examined pricing tactics by PBMs and how they are harming patients across the country.
Fierce Healthcare
SEPTEMBER 22, 2023
Catholic healthcare giant CommonSpirit Health has reported a $1.4 billion operating loss (-4.1% operating margin) and a net loss of $259 million for its 2023 fiscal year, which ended June 30, accor | The 145-hospital nonprofit system's improving volumes were undercut by lagging reimbursement, high costs and a cybersecurity incident. But, fourth-quarter labor costs were somewhat checked by the health system eliminating "approximately 2,000" full-time jobs.
Drug Store News
SEPTEMBER 22, 2023
Walgreen’s partnership with Village Medical—and its investment in micro-fulfillment technology—is crucial to Walgreen’s future in fulfilling its mission of caring for patients.
PharmaVoice
SEPTEMBER 22, 2023
Despite lower-than-expected demand for a competing treatment, DBV’s chief medical officer says the company’s topical skin patch could be a game-changing option for patients.
Fierce Pharma
SEPTEMBER 22, 2023
Fast on the heels of winning a European approval to treat chronic kidney disease (CKD), Eli Lilly and Boehringer Ingelheim's versatile SGLT2 inhibitor Jardiance is expanding its reach in the U.S., | After AstraZeneca's Farxiga won a class-first chronic kidney disease approval back in 2021, Eli Lilly and Boehringer are entering the fray with their SGLT2 drug Jardiance.
STAT
SEPTEMBER 22, 2023
In March 2022, one of us, Kristina, was in Ukraine, running a training on a chilly day. Several hours into the training, one of the soldiers’ faces began to crumple, close to tears. The unit had just received a combat stress management skills training, including a box breathing exercise , in the field outside of a converted military base in Chernihiv near Ukraine’s borders with Belarus and Russia.
Fierce Pharma
SEPTEMBER 22, 2023
It’s not a proper market showdown without all the players. | It’s not a proper market showdown without all the players. In the perioperative treatment of early-stage non-small cell lung cancer with a PD-1/L1 inhibitor, Bristol Myers Squibb is touting a new trial win. The results follow positive readouts from AstraZeneca and Merck.
Pharmaceutical Commerce
SEPTEMBER 22, 2023
An analysis by 3 Axis Advisors has found that there is a large variability in pharmacy reimbursement of prescription drugs depending on PBM contracts with insurers. This creates a system with huge inconsistencies on the prices of both generics and branded products.
Fierce Pharma
SEPTEMBER 22, 2023
As Seagen prepares for its takeover by Pfizer, the company’s Astellas-partnered cancer drug Padcev has chalked up a key trial win—in combination with Merck's Keytruda—in previously untreated metast | In a critical win, the Padcev-Keyturda combo significantly reduced the risk of death in first-line bladder cancer patients who are eligible for platinum-based chemotherapy at an interim analysis of the closely watched EV-302 trial.
Pharmacy Times
SEPTEMBER 22, 2023
Monoclonal antibody treatment resulted in suppression of HIV for more than 3 months, with some continuing to suppress the virus for more than 18 months after treatment stopped.
STAT
SEPTEMBER 22, 2023
And so, another working week will soon draw to a close. Not a moment too soon, yes? This is, you may recall, our treasured signal to daydream about weekend plans. Our agenda includes promenading with the official mascots and a listening party where the rotation will include this , this , this and this , and we will wrap up by observing some ancient rituals.
European Pharmaceutical Review
SEPTEMBER 22, 2023
The National Institute for Health and Care Excellence (NICE) have for the first time, recommended a IL-23p19 targeted biologic for adults with moderate to severe active ulcerative colitis in Great Britain. Eli Lilly’s mirikizumab (OMVOH ® ▼) is indicated for these patients when conventional or biological treatment cannot be tolerated, or the condition has not responded well enough or lost response to treatment.
STAT
SEPTEMBER 22, 2023
Hired someone new and exciting? Promoted a rising star? Finally solved that hard-to-fill spot? Share the news with us, and we’ll share it with others. That’s right. Send us your changes, and we’ll find a home for them. Don’t be shy. Everyone wants to know who is coming and going. And here is our regular feature in which we highlight a different person each week.
Drug Topics
SEPTEMBER 22, 2023
With a laundry list of upcoming changes, it’s more important than ever before that independent pharmacies work together.
Fierce Pharma
SEPTEMBER 22, 2023
A story this week about an FDA Form 483 filing for an Ajinomoto site in San Diego was reported in error. While the site did receive FDA observations in early 2023, the inspection has since closed. | A story published Sept. 19 about an Ajinomoto site in San Diego has been retracted.
European Pharmaceutical Review
SEPTEMBER 22, 2023
According to a report by Research Nester, the global aseptic packaging market is projected to reach a revenue of $35 billion by 2033 and is estimated to reach a compound annual growth rate (CAGR) of 10 percent between 2023 and 2033. Aseptic packaging eliminates the necessity for preservatives and refrigeration which is especially advantageous for medications and vaccines that are sensitive to temperature changes.
Pharmaceutical Technology
SEPTEMBER 22, 2023
JURA Bio has entered into a research collaboration with Replay cell therapy product company Syena for the development of TCR based therapies.
Fierce Healthcare
SEPTEMBER 22, 2023
Access to early cancer screenings and intervention can reduce deaths by 45%, according to the American Cancer Society. However, accessibility remains a significant challenge. | In this week's episode of "Podnosis," Heather Landi from Fierce Healthcare engages in a conversation with Othman Laraki, co-founder and CEO of Color Health. They delve into strategies for boosting screenings and explore the partnership between Color Health and the American Cancer Society, aimed at making co
Expert insights. Personalized for you.
201 
Let's personalize your content